Imagindairy And Ginkgo Bioworks Partner To Develop Animal-Free Non-Whey Dairy Proteins

RTTNews | il y a 297
Stocktwits
Imagindairy And Ginkgo Bioworks Partner To Develop Animal-Free Non-Whey Dairy Proteins

(RTTNews) - Israeli-based foodtech company Imagindairy and Ginkgo Bioworks (DNA) announced Tuesday a new partnership with the aim to deliver a global solution for animal-free non-whey dairy protein production in a highly cost-effective manner.

This collaboration will leverage Ginkgo Protein Expression Services and Imagindairy's process development and scale-up expertise to accelerate the development of functional non-whey dairy proteins.

This is a multi-year program, funded in part by a joint grant from the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.

Imagindairy and Ginkgo have partnered to design an optimized organism capable of cost-effectively producing non-whey dairy proteins. This will allow Imagindairy to remain focused on whey protein production and commercialization while accelerating time to market of non-whey proteins.

Tags: DNA
Stocktwits
read more
Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced Thursday the acquisition of microbial innovation firm AgBiome, Inc.'s platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline.
RTTNews | il y a 281
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

Ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference later on Wednesday, Ginkgo Bioworks (DNA) said it expects to meet its previously disclosed new program and revenue guidance ranges in 2023, based on its preliminary unaudited estimates.
RTTNews | il y a 373
Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Cell programming firm Ginkgo Bioworks Holdings, Inc. (DNA) and biotechnology company Zymergen, Inc. (ZY) announced Monday they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.
RTTNews | il y a 907
Outils
Calendrier Économique
Market Hours
Interest Rates
Holidays Calendar
Marchés Forex
Volatilité Forex
Corrélation Forex
Actualités du Forex
forex analysis
Données COT
Liquidité
Calculatrices Forex
Heat Map du Forex
Indicators Heatmap
Communauté
Communauté
Systèmes
Systèmes les plus populaires
Stratégies
Concours
Graphiques Forex
Sentiment Forex
Indicateur de perspectives
Revues
Courtiers
Prop Trading Firms
Services SPV
Fournisseur de signaux
Services de programmation EA
Affiliate Programs
Services de courtage PAMM
Remise de services de programme
Plateformes de trading
Conseillers Experts
Marchés de crypto-monnaies
Trading Courses
Courtiers
Spreads de Forex
Cotations de courtiers Forex
Swaps de courtiers Forex
Volume du courtier Forex
Promotions des courtiers Forex Broker News
Plateforme
Widgets
Fonctionnalités
API
RSS
Stock Portfolio
Affiliate Software
Graphiques avancés
Support
FAQ
Aide
Contactez-nous
Signaler un bug!
À propos de
Blog
&copier; 2025 Myfxbook Ltd. Tous droits réservés.
AVERTISSEMENT SUR LE RISQUE ÉLEVÉ : Le trading de devises comporte un niveau de risque élevé qui peut ne pas convenir à tous les investisseurs. Leffet de levier crée un risque supplémentaire et une exposition aux pertes. Avant de décider de négocier des devises, examinez attentivement vos objectifs dinvestissement, votre niveau dexpérience et votre tolérance au risque. Vous pourriez perdre une partie ou la totalité de votre investissement initial. Ninvestissez pas largent que vous ne pouvez pas vous permettre de perdre. Renseignez-vous sur les risques associés au trading de devises et demandez conseil à un conseiller financier ou fiscal indépendant si vous avez des questions. Toutes les données et informations sont fournies "en létat", uniquement à titre dinformation, et ne sont pas destinées à des fins de trading ou de recommandation. Les performances passées ne sont pas indicatives des résultats futurs.